03:09:23 EDT Fri 22 Jun 2018
Enter Symbol
or Name

Symbol U : IMGN
Recent Sedar Documents

ImmunoGen, Inc. Announces Webcast of Presentations at Upcoming Investor Conferences

2013-02-05 13:30 ET - News Release

WALTHAM, Mass. -- (Business Wire)

ImmunoGen, Inc. (Nasdaq: IMGN), a biotechnology company that develops anticancer therapeutics using its Targeted Antibody Payload (TAP) technology and antibody expertise, today announced that the following presentations by Company management at upcoming investor conferences will be webcast:

  • 15th Annual BIO CEO & Investor Conference
    9:00 am ET, February 12, 2013 in New York, NY
    Presenter: Daniel Junius, President and CEO
  • Citi 2013 Global Healthcare Conference
    11:05 am ET, February 25, 2013 in New York, NY
    Presenter: Daniel Junius, President and CEO
  • 2013 RBC Capital Markets Global Healthcare Conference
    10:30 am ET, February 26, 2013 in New York, NY
    Presenter: Daniel Junius, President and CEO
  • Cowen and Company 33rd Annual Health Care Conference
    10:00 am ET, March 5, 2013 in Boston, MA
    Presenter: Gregory Perry, Executive Vice President and CFO

The webcasts will be accessible live through the “Investor Information” section of the Company’s website, www.immunogen.com; a replay will be available at the same location for approximately a week.

The Company is also participating in the Credit Suisse One-on-One Healthcare Conference March 5-6, 2013 in London, England.

About ImmunoGen, Inc.

ImmunoGen, Inc. develops targeted anticancer therapeutics using its TAP technology together with the Company’s expertise in monoclonal antibodies and tumor biology. A TAP compound uses a tumor-targeting monoclonal antibody to deliver one of ImmunoGen's purpose-developed cancer-killing agents specifically to tumor cells. Ten TAP compounds are now in clinical testing, of which three are wholly owned by the Company. Marketing applications for trastuzumab emtansine (T-DM1), the most advanced compound using ImmunoGen's TAP technology, are under review in the US and Europe. Roche is developing this compound globally under an agreement between ImmunoGen and Genentech, a member of the Roche Group. More information about ImmunoGen can be found at www.immunogen.com.


For Investors:
ImmunoGen, Inc.
Carol Hausner, 781-895-0600
Executive Director, Investor Relations and Corporate Communications
For Media:
The Yates Network
Barbara Yates, 781-258-6153

Source: ImmunoGen, Inc.

© 2018 Canjex Publishing Ltd. All rights reserved.